UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (date of earliest event reported): October 6,
2008
|
Nevada
|
0-9410
|
90-0031917
|
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(I.R.S.
Employer Identification No.)
|
7327
Oak Ridge Hwy., Knoxville, Tennessee 37931
(Address
of Principal Executive Offices)
(866) 594-5999
(Registrant’s
Telephone Number, Including Area Code)
Check the
appropriate box if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following
provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR.13e-4(c))
Item
8.01 Other Events
Provectus
Pharmaceuticals, Inc. issued the attached press release on October 6, 2008,
announcing that the interim safety analysis on the first 20
subjects in its phase 2 clinical trial for the treatment of metastatic melanoma
has been completed. PV-10 injection was well tolerated by this group, with an
adverse event profile similar to that observed in phase 1. In addition,
long-term survival data for subjects participating in the phase 1 trial were
presented.
Item 9.01
Financial Statements and Exhibits
Exhibit
Number
Description of Exhibit
-----------
-----------------------------
99.1
Press Release of Provectus Pharmaceuticals, Inc. dated October 6,
2008.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned hereunto duly
authorized.
| Provectus Pharmaceuticals, Inc. | |||
|
Date: October
6, 2008
|
By:
|
/s/ Peter Culpepper | |
| Title: Chief Financial Officer | |||